The US Food and Drug Administration (FDA) has approved a pioneering rapid HIV test that can simultaneously detect HIV-1 p24 antigen as well as antibodies to both HIV Type 1 and Type 2.
As well as providing faster diagnosis of HIV infection, the new test is also relatively simple to administer in remote ‘outreach’ settings. These two advantages have huge implications for combating AIDS in sub-Saharan Africa and other underdeveloped areas of the world.
The Alere Determine HIV-1/2 Ag/Ab Combo test is manufactured by Alere’s Israel-based Orgenics subsidiary. It can detect HIV antibodies and the HIV-1 p24 antigen in human serum, plasma, and venous or fingerstick whole-blood specimens.
Read the rest of the article here: http://bit.ly/14H56XK
